Krishnamurthy Shivshanker, MD
Gastroenterology · Houston, TXNPI 1982699682
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 886 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 45 manufacturers reported payments, led by AbbVie at 25.0% of the total.
Across 886 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Gilead$2K
- Johnson & Johnson$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Bristol Myers Squibb$899
- Madrigal Pharmaceuticals$806
- plus $7K from 39 others
Across 149 payments — averaging $2912.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$200K
- Sanofi$149K
- Eli Lilly$56K
- Pfizer$26K
- AbbVie$3K
What the payments were for
- Food & beverage$18,570100%
- Education$660%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPOSIA$727
- Epclusa$471
- Reltone 200 Mg$386
- Reltone 400 Mg$386
- STELARA$361
- REZDIFFRA$277
- VOQUEZNA$248
- Rinvoq$247
- Skyrizi$241
- ZYMFENTRA$126
- Veltassa$122
- Tremfya$121
- DOPTELET$120
- Talicia$109
- LINX Reflux Management System$105
How this compares
$18,636 in reported general payments places this provider in the 85th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 49 | $1,324,851 |
| EpclusaSofosbuvir/Velpatasvir | 16 | $389,803 |
| CreonLipase/Protease/Amylase | 108 | $238,206 |
| RezdiffraResmetirom | 48 | $194,425 |
| Humira(Cf) PenAdalimumab | 17 | $178,186 |
| EntyvioVedolizumab | 12 | $149,505 |
| Dupixent PenDupilumab | 20 | $144,954 |
| ZenpepLipase/Protease/Amylase | 35 | $98,804 |
| Humira PenAdalimumab | 12 | $89,845 |
| XeljanzTofacitinib Citrate | 14 | $80,813 |
| LinzessLinaclotide | 100 | $75,707 |
| Xeljanz XrTofacitinib Citrate | 11 | $71,927 |
| XifaxanRifaximin | 19 | $58,387 |
| OzempicSemaglutide | 30 | $34,304 |
| VemlidyTenofovir Alafenamide | 24 | $34,284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,640 | $1,324,85149 claims |
| GileadEpclusa, Vemlidy | $2,435 | $424,08740 claims |
| AbbVieCreon, Linzess | $4,668 | $313,913208 claims |
| Madrigal PharmaceuticalsRezdiffra | $806 | $194,42548 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $1,425 | $149,50512 claims |
| Aimmune Therapeutics, Inc.Zenpep | $184 | $98,80435 claims |
| PfizerXeljanz | $701 | $80,81314 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $470 | $67,37036 claims |
| Novo NordiskOzempic | $42 | $34,30430 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $364 | $25,59334 claims |
| Lilly USA, LLCMounjaro | $169 | $16,81717 claims |
| AstraZenecaNexium | $20 | $4,17812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Houston
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Brooks CashHouston$867K
- Mohamed OthmanHouston$777K
- Isaac RaijmanHouston$565K
- Kalpesh PatelHouston$382K
- Victor Ankoma-SeyHouston$340K
- John VierlingHouston$270K
- George TriadafilopoulosHouston$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.